Mucopolysaccharaidosis
Reading File
Finding Sources
Searching PubMed
mucopolysaccharidosis
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have a comprehensive picture of mucopolysaccharidoses. Let me compile the full answer.
Mucopolysaccharidoses (MPS)
Definition
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by defective stepwise degradation of glycosaminoglycans (GAGs) - formerly called mucopolysaccharides. GAGs include dermatan sulfate, heparan sulfate, keratan sulfate, and chondroitin sulfate, which are components of proteoglycans in the extracellular matrix and cell surfaces. Genetic defects in any one of the dozen-plus lysosomal enzymes required for their catabolism lead to progressive accumulation of GAG metabolites in lysosomes, disrupting cellular physiology throughout the body.
- Goldman-Cecil Medicine, Chapter 239
Epidemiology
All MPS disorders are rare, each occurring with an incidence of one or fewer per 100,000 births, and show no ethnic predilection. With the exception of MPS II (Hunter syndrome), which is X-linked, all types are autosomal recessive.
Classification - Types and Eponyms
| Type | Eponym | Key Clinical Features | Enzyme Defect |
|---|---|---|---|
| MPS IH | Hurler syndrome | Dysostosis multiplex (DM), short stature; intellectual disability (ID); corneal clouding; hepatosplenomegaly (HS); heart disease; death in childhood | α-L-iduronidase |
| MPS IS | Scheie syndrome | Coarse facies; stiff joints; corneal clouding; aortic valve disease; normal intelligence and lifespan | α-L-iduronidase |
| MPS II | Hunter syndrome (X-linked) | Severe: coarse facies, DM, HS, ID, no corneal clouding, death by late adolescence. Mild form: coarse facies, short stature, normal intelligence, survives to adulthood | Iduronate sulfatase |
| MPS IIIA | Sanfilippo A | Severe ID and hyperactivity; mild somatic changes | Heparan N-sulfatase |
| MPS IIIB | Sanfilippo B | Same as IIIA | α-N-acetylglucosaminidase |
| MPS IIIC | Sanfilippo C | Same as IIIA | Acetyl-CoA: α-D-glucosaminide acetyltransferase |
| MPS IIID | Sanfilippo D | Same as IIIA | N-acetylglucosamine 6-sulfatase |
| MPS IVA | Morquio A | Severe skeletal dysplasia; odontoid hypoplasia; myelopathy; normal intelligence; no ID | Galactosamine 6-sulfatase |
| MPS IVB | Morquio B | Similar skeletal features to IVA; degenerative course | β-galactosidase |
| MPS VI | Maroteaux-Lamy | Severe skeletal changes, kyphoscoliosis, pectus carinatum, restrictive lung disease; normal intelligence | N-acetylgalactosamine 4-sulfatase |
| MPS VII | Sly syndrome | Variable; hydrops fetalis possible | β-glucuronidase |
Table 239-1, Goldman-Cecil Medicine
Pathobiology
Mechanism: Catabolism of GAG proceeds normally until the step requiring the defective enzyme. Accumulation occurs within lysosomes of mesenchymal cells, endothelium, and (in most types) neurons, causing widespread, progressive cellular dysfunction.
Pathology (gross):
- Hepatosplenomegaly
- Dysostosis multiplex - marked skeletal alterations causing short stature and thoracic cage deformity
- Thickening and narrowing of airways and arteries
- Coarsening of facial features
Pathology (microscopic):
- Mesenchymal cells show cytoplasm full of apparently empty vacuoles (lysosomes emptied of GAG by fixation)
- Cultured cells show greatly enlarged lysosomes filled with granular material
Clinical Manifestations
All manifestations worsen with age, and some are present from early development. A wide clinical spectrum exists even within single MPS types:
- Growth: Short stature; dysostosis multiplex
- CNS: Intellectual disability (MPS I, II, III, VII); progressive speech impairment; behavioral disturbances; sleep disorders (especially MPS III - Sanfilippo); communicating hydrocephalus
- Eyes: Corneal clouding (MPS I, IV, VI); absent in MPS II (Hunter)
- Cardiovascular: Heart valve disease; coronary involvement
- Airway: Soft tissue GAG deposition causing progressive narrowing; high anesthetic risk
- Musculoskeletal: Joint stiffness; cervical myelopathy (MPS I, II, VI - from dural thickening)
- Other: Hearing loss; carpal tunnel syndrome
MPS III (Sanfilippo) specific: Primarily CNS manifestations, mild somatic involvement. Progressive speech impairment, severe behavioral and sleep disturbances, then unrelenting loss of skills leading to a vegetative state; death often in the third decade.
MPS IV and VI: Severe skeletal dysplasia; normal intelligence. Both show kyphoscoliosis, pectus carinatum, restrictive lung disease.
Diagnosis
- Screening: Measurement of urinary GAG concentration and fractionation; analysis of urine oligosaccharides
- Confirmatory: Assay of specific enzyme activity in leukocytes
- Molecular: Gene sequencing for confirmation and carrier/prenatal testing
Treatment
Enzyme Replacement Therapy (ERT) is available for:
- MPS I - laronidase (α-L-iduronidase)
- MPS II - idursulfase (iduronate sulfatase)
- MPS IVA - elosulfase alfa
- MPS VI - galsulfase
- MPS VII - vestronidase alfa
Hematopoietic stem cell transplantation (HSCT) - most effective in MPS I Hurler (best outcomes if done early, before 2 years of age)
Supportive / surgical:
- Physical therapy to optimize joint mobility and function
- Airway management (progressive soft tissue narrowing; all anesthesia is high risk)
- Surveillance for cervical myelopathy in MPS I, II, and VI (dural thickening; may present with reduced endurance before ascending paralysis)
- Surgery for carpal tunnel syndrome; cardiovascular surgery for valve/coronary disease
Emerging therapies:
- Gene therapy - promising experimental approach for MPS I (Hurler) and MPS VI
- Substrate reduction therapy (genetic approaches) - under investigation per recent systematic reviews
Key Clinical Pearls
| Feature | Note |
|---|---|
| Only X-linked MPS | MPS II (Hunter syndrome) |
| No corneal clouding | MPS II (Hunter), MPS III (Sanfilippo) |
| Normal intelligence | MPS IS (Scheie), MPS IV (Morquio), MPS VI (Maroteaux-Lamy) |
| Severe CNS, mild somatic | MPS III (Sanfilippo) |
| Atlantoaxial instability / odontoid hypoplasia | MPS IVA (Morquio A) - surgical risk |
| Highest anesthesia risk | All MPS - narrow airways and cervical instability |
Recent Evidence (2024-2026)
A 2024 systematic review of intravenous idursulfase (PMID: 39201256) confirmed its effectiveness for MPS II, and a systematic review on substrate reduction therapy (PMID: 39177875) highlighted genetic SRT as an emerging strategy for lysosomal storage diseases including MPS. Airway complications - including tracheostomy requirements in pediatric MPS patients - were addressed in a 2024 systematic review (PMID: 39581170).
Sources: Goldman-Cecil Medicine International Edition (2 Vol. Set), Chapter 239 (Inherited Diseases of Connective Tissue) and Chapter 192 (Lysosomal Storage Diseases)
History taking in cerebral palsy case in one year old child
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive content. Let me compile the full structured history-taking guide.
History Taking in a Cerebral Palsy Case - 1-Year-Old Child
Clinical note: Diagnosis of CP before 2 years is challenging. One study found 55% of children diagnosed with CP at 1 year did not meet criteria by age 7. This does not mean history taking is less important - it is the primary diagnostic tool at this age. Campbell's Operative Orthopaedics, 15th Ed.
Structure of History
At 1 year, the history is taken entirely from the parents/caregiver. The goal is to:
- Identify risk factors for brain injury (antenatal, perinatal, postnatal)
- Document developmental regression or delay (motor milestones)
- Assess functional limitations and associated problems
- Rule out progressive/genetic conditions that mimic CP
1. Presenting Complaint
- What prompted the visit? (Concern about motor delay, abnormal tone, asymmetric limb use, not walking by expected age)
- When was the concern first noticed, and by whom?
- Is the condition static (no regression) or getting worse? (Worsening suggests a progressive disorder, not CP)
2. Antenatal History (Prenatal Period)
Ask about conditions that cause congenital CP (85-90% of all CP):
| Area | Specific Questions |
|---|---|
| Maternal health | Infections during pregnancy (TORCH - toxoplasmosis, rubella, CMV, herpes); maternal fever; thyroid disease; diabetes; hypertension; antiphospholipid syndrome; autoimmune disease |
| Fetal growth | Any scans showing intrauterine growth restriction (IUGR); abnormal antenatal ultrasound findings (brain anomalies, ventriculomegaly) |
| Multiple pregnancy | Twins/triplets? Twin-to-twin transfusion syndrome? (Multiple births carry higher CP risk, mainly mediated through prematurity) |
| Drug/teratogen exposure | Medications, alcohol, smoking, substance use during pregnancy |
| Consanguinity | Parental consanguinity (raises suspicion for genetic/neurometabolic disorder mimicking CP) |
| Family history | Other children or family members with similar problems; spastic paraparesis in the family; known genetic conditions |
3. Perinatal History (Birth and Neonatal Period)
This is the most critical component of history in CP:
Gestational Age and Birth Weight
- Prematurity is the strongest risk factor
- Very preterm (<32 weeks): incidence of CP ~8.7%
- Late preterm (34-37 weeks): ~0.6%
- Term (>37 weeks): ~0.1-0.2%
- Birth weight - very low birth weight (<1500 g) is an independent predictor
Mode and Conduct of Delivery
- Normal vaginal delivery / instrumental (forceps/vacuum) / emergency LSCS?
- Was there any prolonged/obstructed labor?
- Cord prolapse, cord around neck, abruptio placentae, placenta previa?
- Any fetal distress during labor?
Neonatal Status at Birth
- APGAR scores at 1 min and 5 min (low scores suggest perinatal asphyxia)
- Did the baby cry immediately at birth?
- Was resuscitation required? (bag-mask, intubation, cardiac compression)
- Meconium-stained liquor?
Neonatal Illness / NICU Admission
- Hypoxic-ischemic encephalopathy (HIE) - most commonly specified cause
- Neonatal seizures - type, onset, treatment
- Neonatal jaundice - level of hyperbilirubinemia; exchange transfusion? (Kernicterus causes dyskinetic CP)
- Intraventricular hemorrhage (IVH) / periventricular leukomalacia (PVL) - documented on neonatal ultrasound? Grade?
- Sepsis / meningitis during neonatal period
- Hypoglycemia - duration and severity
- Duration of NICU stay; need for ventilation; oxygen therapy
"Obtaining a birth history (e.g., Apgar score, history of anoxia, jaundice, or traumatic birth) and early developmental abnormalities is essential when considering the possibility of cerebral palsy." - Bradley & Daroff's Neurology
4. Postnatal History (0-12 months)
Acquired CP accounts for ~10-15% of cases:
- Meningitis or encephalitis after the neonatal period (2nd most common cause of acquired CP)
- Perinatal stroke (most common cause of hemiplegic CP) - was it recognized? History of thromboembolism?
- Traumatic head injury - accidental or abusive (non-accidental head injury)
- Severe dehydration, metabolic crises, near-drowning
- Prolonged seizures (status epilepticus)
5. Developmental History
This is central to the assessment at 1 year. Ask about motor milestones (most relevant in CP) and other domains:
Motor Milestones
| Milestone | Expected Age | Ask: achieved or not? |
|---|---|---|
| Head control (prone) | 3-4 months | |
| Rolls over | 4-5 months | |
| Sits without support | 6-8 months | |
| Stands with support | 9-10 months | |
| Pulls to stand | 10-12 months | |
| Cruising / walking | 12-15 months |
- Hand preference before 12-18 months is abnormal - suggests hemiplegia on the contralateral side
- Ask: "Does the baby use both hands equally?" - asymmetric use is a red flag
Other Developmental Domains (Milestones at 12 months)
- Communication/Language: Babbling at 6 months? Single words ("mama/dada") by 12 months? Social smile by 6-8 weeks?
- Social: Responds to name? Stranger anxiety? Follows simple commands?
- Fine motor: Pincer grasp (thumb-index, normally by 9-10 months)?
- Cognitive: Object permanence? Cause-and-effect play?
Important: Is there evidence of regression (loss of previously acquired skills)? If yes - this strongly argues against CP and points to a progressive metabolic/neurodegenerative disorder.
6. Feeding History
Feeding problems are common and directly related to oromotor dysfunction in CP:
- Difficulty sucking from birth (neonatal feeding difficulties)?
- Excessive drooling?
- Choking or gagging during feeds?
- Slow feeding (>30 minutes per feed)?
- Recurrent respiratory infections (aspiration)?
- Faltering growth / weight gain?
7. Associated Problems History ("Red Flags" and Co-morbidities)
CP is rarely isolated - enquire specifically:
| System | Ask About |
|---|---|
| Seizures | Age of onset; type (tonic, clonic, spasms); frequency; current medications |
| Vision | Does the child track objects? Turn to visual stimuli? Squint (strabismus)? |
| Hearing | Turns to sounds? Neonatal hearing screen result? History of repeated ear infections |
| Sleep | Sleep disturbances (common in CP) |
| Behavior | Excessive irritability? Inconsolable crying? |
| Pain | Any signs of hip pain or discomfort |
8. Family History
- Other children with similar problems?
- Any family members with spastic paraparesis, intellectual disability, or neuromuscular disease?
- Consanguinity between parents?
- Any early unexplained infant deaths in the family?
- (Pattern of affected family members may suggest genetic disorder rather than CP)
9. Social History
- Who are the primary caregivers?
- Any concerns about child abuse or neglect (non-accidental injury)?
- Parental occupation and education (impacts on stimulation and rehabilitation adherence)
- Access to therapy services
Red Flags in History That Suggest It May NOT be CP
These from history should prompt consideration of alternative diagnoses (neurogenetic, metabolic):
- No identifiable perinatal risk factor - especially in a severe presentation
- Developmental regression - loss of skills already acquired
- Progressively worsening symptoms
- Multiple affected family members - especially with a suggestible inheritance pattern
- Isolated hypotonia without spasticity or abnormal movements
- Prominent extrapyramidal symptoms without explanation (e.g., no basal ganglia injury on imaging)
"Severe symptoms in the absence of history of perinatal injury, developmental regression, progressively worsening symptoms... raise concern for an underlying neurogenetic cause." - Bradley & Daroff's Neurology in Clinical Practice
Summary Framework for History Taking (MNEMONIC: APFD + DAFA)
| Letter | Domain |
|---|---|
| A | Antenatal history (infections, growth, anomalies) |
| P | Perinatal history (delivery, APGAR, neonatal illness) |
| F | Family and social history |
| D | Developmental milestones (motor first, then others) |
| D | Diagnosis - presenting complaint and onset |
| A | Associated problems (seizures, vision, hearing, feeding) |
| F | Feeding history |
| A | Ask about regression (key discriminator from progressive disease) |
Sources: Campbell's Operative Orthopaedics 15th Ed. 2026; Bradley and Daroff's Neurology in Clinical Practice; Bailey and Love's Short Practice of Surgery 28th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.